118 related articles for article (PubMed ID: 1803863)
41. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
Lissoni P; Mandalà M; Brivio F
Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
[TBL] [Abstract][Full Text] [Related]
42. In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
Lissoni P; Barni S; Tisi E; Rovelli F; Pittalis S; Rescaldani R; Vigoré L; Biondi A; Ardizzoia A; Tancini G
Eur J Cancer; 1993; 29A(8):1127-32. PubMed ID: 8390845
[TBL] [Abstract][Full Text] [Related]
43. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
[TBL] [Abstract][Full Text] [Related]
44. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients.
Lissoni P; Malugani F; Bukovec R; Bordin V; Perego M; Mengo S; Ardizzoia A; Tancini G
Neuro Endocrinol Lett; 2003; 24(1-2):83-5. PubMed ID: 12743539
[TBL] [Abstract][Full Text] [Related]
45. Anti-angiogenic activity of melatonin in advanced cancer patients.
Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
[TBL] [Abstract][Full Text] [Related]
46. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
Lissoni P; Vigorè L; Rescaldani R; Rovelli F; Brivio F; Giani L; Barni S; Tancini G; Ardizzoia A; Viganò MG
J Biol Regul Homeost Agents; 1995; 9(4):155-8. PubMed ID: 8844341
[TBL] [Abstract][Full Text] [Related]
47. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
[TBL] [Abstract][Full Text] [Related]
48. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer.
Lissoni P; Barni S; Archili C; Cattaneo G; Rovelli F; Conti A; Maestroni GJ; Tancini G
Anticancer Res; 1990; 10(3):753-7. PubMed ID: 2142395
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
Lissoni P; Barni S; Cazzaniga M; Ardizzoia A; Rovelli F; Brivio F; Tancini G
Oncology; 1994; 51(4):344-7. PubMed ID: 8208518
[TBL] [Abstract][Full Text] [Related]
50. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
[TBL] [Abstract][Full Text] [Related]
51. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
52. Inhibitory effect of interleukin-3 on interleukin-2-induced cortisol release in the immunotherapy of cancer.
Lissoni P; Rovelli F; Tancini G; Tisi E; Rivolta MR; Ardizzoia A; Brivio F
J Biol Regul Homeost Agents; 1992; 6(4):113-5. PubMed ID: 1338354
[TBL] [Abstract][Full Text] [Related]
53. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.
Brown RR; Lee CM; Kohler PC; Hank JA; Storer BE; Sondel PM
Cancer Res; 1989 Sep; 49(17):4941-4. PubMed ID: 2788032
[TBL] [Abstract][Full Text] [Related]
54. A new approach to adoptive immunotherapy of cancer using tumorcytotoxic macrophages grown from peripheral blood monocytes.
Andreesen R; Scheibenbogen C; Brugger W; Krause S; Leser HG; Kopf S; Engler H; Schümichen C; Löhr GW
Cancer Detect Prev; 1991; 15(5):413-21. PubMed ID: 1751953
[TBL] [Abstract][Full Text] [Related]
55. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
Aldeghi R; Lissoni P; Barni S; Ardizzoia A; Tancini G; Piperno A; Pozzi M; Ricci G; Conti A; Maestroni GJ
Eur J Cancer; 1994; 30A(2):167-70. PubMed ID: 8155391
[TBL] [Abstract][Full Text] [Related]
56. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Paolorossi F; Brivio F; Perego M; Tancini G; Conti A; Maestroni G
Tumori; 1992 Dec; 78(6):383-7. PubMed ID: 1297233
[TBL] [Abstract][Full Text] [Related]
57. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
Lissoni P
Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384
[TBL] [Abstract][Full Text] [Related]
58. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
Lissoni P; Giani L; Zerbini S; Trabattoni P; Rovelli F
Nat Immun; 1998; 16(1):27-33. PubMed ID: 9789122
[TBL] [Abstract][Full Text] [Related]
59. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia.
Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Ardizzoia A; Tancini G
Oncology; 1995; 52(5):360-2. PubMed ID: 7637951
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Rovelli F; Cazzaniga M; Brivio F; Piperno A; Aldeghi R; Fossati D
Br J Cancer; 1993 Jun; 67(6):1404-7. PubMed ID: 8512825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
